Skip to main content
Equibles
LGND logo

LGND · Ligand Pharmaceuticals Inc · Earnings Call Transcripts & Audio

Track LGND — free

Use LGND with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LGND.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$285.27 +0.80 (+0.28%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$5.67B
Shares
19.94M

Ligand Pharmaceuticals Inc Earnings Call Transcripts

Quarterly earnings calls for Ligand Pharmaceuticals Inc (LGND), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼0.8% $59.22M $404,000 '22 Q3 22-11-07 ▼10.7% $50.38M −$17.48M '22 Q4 23-02-22 ▲20.4% $43.98M $41.95M '23 Q1 23-05-04 ▼47.4% $26.37M $2.29M '23 Q2 23-08-08 ▼44.5% $32.87M −$10.27M '23 Q3 23-11-08 ▼44.2% $28.10M $18.19M '23 Q4 24-02-27 ▼29.6% $30.98M $86.14M '24 Q1 24-05-07 ▲57.5% $41.53M −$51.91M '24 Q2 24-08-06 ▲57.6% $51.81M −$7.17M '24 Q3 24-11-07 ▲52.4% $42.81M −$31.09M '24 Q4 25-02-27 ▲46.3% $45.33M −$42.45M '25 Q1 25-05-08 ▲14.7% $47.63M $4.85M '25 Q2 25-08-07 ▲122.8% $115.46M $117.27M '25 Q3 25-11-06 ▲39.4% $59.67M $44.78M '25 Q4 26-02-26 ▲14.1% $51.72M −$13.35M '26 Q1 26-05-07 LATEST ▲33.7% $63.69M $48.51M '26 Q2 26-08-06
Conference
Investor event
2026-09-14
Ligand Pharmaceuticals Inc (LGND) September 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-10
Ligand Pharmaceuticals Inc (LGND) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-08
Ligand Pharmaceuticals Inc (LGND) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Ligand Pharmaceuticals Inc (LGND) Q2 2026 Earnings Call Transcript
Revenue
$63.69M
▲ 33.7% YoY
Diluted EPS
$2.22
▲ 825% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Ligand Pharmaceuticals Inc (LGND) Q1 2026 Earnings Call Transcript
Confident tone Filspari (sparsentan) franchise Pelvella Qtorin rapamycin (MLM) Investor day and long-term outlook
Revenue
$51.72M
▲ 14.1% YoY
Diluted EPS
$-0.67
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Ligand Pharmaceuticals Inc (LGND) Q4 2025 Earnings Call Transcript
Confident tone FILSPARI FSGS and IgAN market opportunity Royalty portfolio growth and key products Pelvella/SELVA trial and QTORIN rapamycin
Revenue
$59.67M*
▲ 39.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Ligand Pharmaceuticals Inc (LGND) Q3 2025 Earnings Call Transcript
Confident tone ZELSUVMI / Pelthos launch Product launches (Ohtuvayre, FILSPARI, CAPVAXIVE) Development-stage pipeline (Palvella, AT292)
Revenue
$115.46M
▲ 122.8% YoY
Diluted EPS
$5.68
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Ligand Pharmaceuticals Inc (LGND) Q2 2025 Earnings Call Transcript
Confident tone O2vir / Verona / Merck acquisition Pelthos / Zelsuvmi launch and value creation Pipeline catalysts (Filspari, Agenus, Alda, Qarziba)
Revenue
$47.63M
▲ 14.7% YoY
Diluted EPS
$0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Transcript
Confident tone Commercial product launches (Ohtuvayre, Capvaxive, Zelsuvmi) Filspari label expansion and FSGS sNDA NITRICIL platform and special situations
Revenue
$45.33M
▲ 46.3% YoY
Diluted EPS
$-2.21
▼ 146.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Transcript
Confident tone Castle Creek / D-Fi investment Business development pipeline and opportunity set Zelsuvmi / Pelthos launch and partnership search
Revenue
$42.81M*
▲ 52.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Transcript
Confident tone Travere FILSPARI Ohtuvayre and CAPVAXIVE launches Revenue growth and guidance
Revenue
$51.81M
▲ 57.6% YoY
Diluted EPS
$-0.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Transcript
Confident tone Royalty Portfolio Expansion Investment Activity and Capital Deployment Captisol Business Review
Revenue
$41.53M
▲ 57.5% YoY
Diluted EPS
$-2.88
▼ 2315.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Ligand Pharmaceuticals Inc (LGND) Q1 2024 Earnings Call Transcript
Confident tone Partnered pipeline catalysts Royalty aggregation and investment strategy Zelsuvmi and Pelthos Therapeutics
Revenue
$30.98M
▼ 29.6% YoY
Diluted EPS
$4.75
▲ 103.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Ligand Pharmaceuticals Inc (LGND) Q4 2023 Earnings Call Transcript
Confident tone Approved Products and Commercial Catalysts Pipeline PDUFA Approvals Teriparatide and Competitive Risks
Revenue
$28.10M*
▼ 44.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Ligand Pharmaceuticals Inc (LGND) Q3 2023 Earnings Call Transcript
Revenue
$32.87M
▼ 44.5% YoY
Diluted EPS
$-0.59
▼ 3050% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Ligand Pharmaceuticals Inc (LGND) Q2 2023 Earnings Call Transcript
Revenue
$26.37M
▼ 47.4% YoY
Diluted EPS
$0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Ligand Pharmaceuticals Inc (LGND) Q1 2023 Earnings Call Transcript
Revenue
$43.98M
▲ 20.4% YoY
Diluted EPS
$2.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Ligand Pharmaceuticals Inc (LGND) Q4 2022 Earnings Call Transcript
Revenue
$50.38M
▼ 10.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Ligand Pharmaceuticals Inc (LGND) Q3 2022 Earnings Call Transcript
Revenue
$59.22M
▼ 0.8% YoY
Diluted EPS
$0.02
▼ 97.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Ligand Pharmaceuticals Inc (LGND) Q2 2022 Earnings Call Transcript
Revenue
$50.13M
▼ 36.4% YoY
Diluted EPS
$-0.05
▼ 104.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Ligand Pharmaceuticals Inc (LGND) Q1 2022 Earnings Call Transcript
Revenue
$36.52M
▼ 21.6% YoY
Diluted EPS
$-0.91
▼ 238.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
Ligand Pharmaceuticals Inc (LGND) Q4 2021 Earnings Call Transcript
Revenue
$56.40M
▼ 19.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Ligand Pharmaceuticals Inc (LGND) Q3 2021 Earnings Call Transcript
Revenue
$59.69M
▲ 42.6% YoY
Diluted EPS
$0.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Ligand Pharmaceuticals Inc (LGND) Q2 2021 Earnings Call Transcript
Revenue
$78.85M
▲ 90.4% YoY
Diluted EPS
$1.12
▲ 35.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-03
Ligand Pharmaceuticals Inc (LGND) Q1 2021 Earnings Call Transcript
Revenue
$46.59M
▲ 40.5% YoY
Diluted EPS
$0.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
Ligand Pharmaceuticals Inc (LGND) Q4 2020 Earnings Call Transcript
Revenue
$69.99M
▲ 159.2% YoY
Diluted EPS
$0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-30
Ligand Pharmaceuticals Inc (LGND) Q3 2020 Earnings Call Transcript
Revenue
$41.85M
▲ 68.7% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-03
Ligand Pharmaceuticals Inc (LGND) Q2 2020 Earnings Call Transcript
Revenue
$41.42M
▲ 65.8% YoY
Diluted EPS
$0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Ligand Pharmaceuticals Inc (LGND) Q1 2020 Earnings Call Transcript
Revenue
$33.16M
▼ 23.7% YoY
Diluted EPS
$-0.91
▼ 104.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-06
Ligand Pharmaceuticals Inc (LGND) Q4 2019 Earnings Call
Revenue
$27.00M
▼ 54.7% YoY
Diluted EPS
$-0.27
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–30 of 30 earnings calls
Key facts CIK 886163 CUSIP 53220K504 13F (30d) 16 filings 15 filers Visit website Investor relations